Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.73 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.73 |
| ▸ | EGFR | P00533 | 14/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | MLNR | O43193 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18870128 | 0.92 | MKNK2 (0.75) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL17822329 | 0.92 | MKNK2 (0.74) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL29525375 | 0.92 | MKNK2 (0.74) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL14661053 | 0.89 | MKNK2 (0.70) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL30219237 | 0.89 | MKNK2 (0.70) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL21729615 | 0.89 | MKNK2 (0.70) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL31366682 | 0.89 | MKNK2 (0.70) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL29555776 | 0.89 | MKNK2 (0.70) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL28626837 | 0.88 | MKNK1 (0.66) | MKNK2MKNK1EGFRHDAC1HDAC3 | |
| SCHEMBL28634524 | 0.88 | MKNK1 (0.66) | MKNK2MKNK1EGFRHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180477-B2 | Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof | ASTRAZENECA AB (SE) | 2021-11-23 | — | — | US | disclosed |
| US-11180477-B2 | Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof | ASTRAZENECA AB (SE) | 2021-11-23 | — | — | US | disclosed |
| US-20210122734-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA UK LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-20210122734-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA UK LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-3411038-B1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA AB (SE) | 2020-09-09 | — | — | EP | disclosed |
| EP-3411038-B1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA AB (SE) | 2020-09-09 | — | — | EP | disclosed |
| EP-3411038-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | Astrazeneca AB (SE) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134051-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA AB (SE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134051-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA AB (SE) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180477-B2 | Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof | JAK2, JAK1, ROS1 | MKNK2 211/4885MKNK1 201/4885EGFR 49/4885 |
| US-20210122734-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | JAK2, JAK1, ABL1 | MKNK2 282/4885MKNK1 314/4885EGFR 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.